3.45k followers • 30 symbols Watchlist by Yahoo Finance
Follow this list to discover and track stocks with the greatest 52-week gain. These are stocks whose price has increased the most over the past 52 weeks (percent change). This list is generated daily, the gains are based on today's closing price and limited to the top 30 stocks that meet the criteria.
When an investment vehicle offers a high rate of return in a short period of time, investors know this means the investment is risky. Given enough time, many investments have the potential to double the initial principal amount, but many investors are instead attracted to the lure of high yields in short periods of time despite the possibility of unattractive losses. Make no mistake, there is no guaranteed way to double your money with any investment.
The midday reaction was rather dull considering what a big mover Nvidia stock tends to be, although long-time shareholders are likely content with Friday's price action. Many are wondering what's next for Nvidia. Bears are arguing that Nvidia stock's failure to rally indicates poor price action.
Roku, Guardant Health, and Carvana have all soared to start the year. Should the buyer beware or let the good times roll?
Pot stocks were more concerned with supporting inflated valuations than meeting grow expectations, according to this prominent cannabis CEO.
Cannabis stocks and exchange-traded funds fell Friday. Among cannabis stocks tracked by TheStreet, two rose while nine fell. General Cannabis shares rose 6 cents, or 3.77%, to $1.65. Tilray shares fell $1.
CEO of Coupa Software Inc (NASDAQ:COUP) Robert Bernshteyn sold 63,225 shares of COUP on 05/17/2019 at an average price of $110.19 a share.
The "Cannabis Craze" had everyone and their brother buying up marijuana stocks. These cannabis stocks didn't have enough free-floating shares to cover the massive amount of buy interest leading them to skyrocketed at the end of 2018 far above their fair value.
Shares of Facebook (NASDAQ:FB) haven't been able to sidestep the selling pressure over the past few weeks. Shares have pulled back, with FB stock falling from roughly $200 down to $180. However, the pullback has been very orderly so far and is even finding some moving average support.Source: Shutterstock Is this investors' chance to hop on the Facebook train or should they stay clear in the event of more selling?With the trade war hitting U.S. stocks, virtually all industries are under pressure, even though not all of them are impacted by the trade war. For instance, cloud companies like Adobe (NASDAQ:ADBE) or Salesforce (NYSE:CRM) won't see their businesses impacted by the trade war. Nor will Twilio (NYSE:TWLO) or Splunk (NASDAQ:SPLK). Worth mentioning is that Facebook isn't allowed in China, although its WeChat has plenty of global exposure.InvestorPlace - Stock Market News, Stock Advice & Trading TipsMy point is, even though some of the companies above aren't impacted by the trade war, their stocks are still under pressure. FB stock is no exception either. Maybe the indices have already bottomed from these headlines, but it doesn't feel like it. If we have one or two more down legs to do go, investors will get a better shot at Facebook stock. That said, traders have a reasonable risk/reward situation with FB right now, should the markets hold up. Trading FB Stock Click to EnlargeSo far, uptrend support (blue line) and the 50-day moving average are holding up for FB stock. That's a perfect spot for traders to watch, too. A pullback in a strong stock to its 50-day usually draws in buyers, even if only for the short-term. Facebook at least has that going for it right now. * 7 Tech Stocks to Buy That Are Also Perfect for Retirement The key is to see what kind of bounce we get. Is it a modest 1% to 2% rally or does it send FB stock back to recent highs near $195? If it clears $195, $200 is on deck. Over the 61.8% Fibonacci retracement at $182.10 increases the odds for a retest of the 20-day moving average and gives some momentum to bulls.Should the selling accelerate in the overall market and FB stock gets pulled down, there are levels of support below too. A price of $170.82 marks a 50% retracement and down near $159.50 is the 38.2% retracement. The latter comes into play near the 200-day moving average and is a key level of support. Conveniently, $170 could be decent support too, it just depends on the aggressiveness of sellers should we get a pullback down to these levels.We may not see that type of decline, but if we do, it will pay to know where FB stock can hold up. Valuing Facebook StockIt was like the sky was falling with Facebook stock over the past year, as investors were dumping the social media giant hand over fist. That's despite it having the best financials and metrics compared to peers like Twitter (NYSE:TWTR) and Snap (NYSE:SNAP).Privacy concerns and worries about leadership caused investors to puke up the stock. Never mind that FB stock has one of the strongest balance sheets in the stock market and is a cash-flow machine.Analysts expect the company to earn $7.05 per share this year. That's down almost 7% from the prior year. The plus side is that they expect 32% earnings growth to $9.32 per share in fiscal 2020. On the revenue front, growth is doing anything but slowing. Estimates call for 24% growth this year and 21% next year. * 7 Stocks to Buy that Lost 10% Last Week Social media is far too efficient for businesses to ignore when it comes to advertising and it's far too addicting for users to put down. So long as that remains the case, Facebook will be in business. That bodes well for long-term investors, particularly given the balance sheet strength of FB stock.Long-term investors may consider waiting for a larger correction in FB stock should they want to bet on the continued growth in social media. Otherwise they could consider a nibble of Facebook near current levels.Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, Bret Kenwell did not hold a position in any of the aforementioned securities. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 Stocks to Buy that Lost 10% Last Week * Top 7 Dow Jones Stocks of 2019 -- So Far * 5 Service Stocks That Can Win the Trade War -- According to Goldman Sachs Compare Brokers The post Can Facebook Stock Rally Back to $200? appeared first on InvestorPlace.
See who joins FANG stocks Netflix and Facebook, plus Veeva Systems, ServiceNow, Paycom, Visa, and Atlassian on this list of the fastest-growing large-cap stocks.
Are marijuana stocks on U.S. exchanges a good buy now? The marijuana industry gets a lot of hype, but look past the smoke and analyze pot stocks on their fundamentals and technicals.
After a revenue beat Tilray Inc (NASDAQ:TLRY) saw its stock jump 5% for the day. However, that optimism has faded rather quickly, and Tilray stock has not been able to capitalize on that momentum.Source: Shutterstock Unequivocally, it has been a wild ride for Tilray investors. Last fall, against a very frothy overall market and marijuana stocks going more mainstream, the stock price exceeded the $200 mark before getting cut down by three quarters, trading at less than $50 per share as of this writing. * 6 Chinese Stocks That Could Pop On a Trade Deal Still though, I remain cautious on Tilray stock. The company hit a major milestone by landing a partnership with Novartis AG (NYSE:NVS), the Swiss pharmaceutical company, late last year. That's certainly been a positive catalyst, but after all the hype, investors need to see meaningful progress toward a more profitable future.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Tilray Stock Has a Mixed First QuarterA lot of the focus immediately after earnings was around revenues. TLRY delivered a massive 195 increase in year-over-year revenues. The legalization of marijuana use in Canada for adults last year in addition to hemp food sales from Tilray's acquisition of Manitoba Harvest were big drivers.Gross margins also saw a slight increase, but despite these positive signs, net losses for the quarter increased dramatically. Last quarter $5 million to $30 million most recently. For a growth company, it's not necessarily unexpected. Expansion costs money as companies need to lay the foundation for future endeavors, but the point is that it's naive to look only at the revenue beat and think TLRY stock is headed for the sky.Total kilogram equivalents sold did double to 3,012 kilograms, but compare that to fellow competitor Canopy Growth (NYSE:CGC) that sold 10,102 kilogram equivalents in the most recent quarter and has a higher pricing structure.TLRY is still doesn't have pricing figured out seeing as average net selling price per gram decreased over the prior year period. As the space gets more and more competitive, TLRY needs to optimize this quickly as increasing supply toward medical and consumer purposes will put pressure on prices. The trend is not going in the right direction. Tilray Stock Is OvervaluedUltimately, TLRY stock looks lofty in terms of valuation. This, of course, does not mean the stock cannot get more expensive from here, but it's not a screaming buy despite some decent first quarter numbers.Tilray's consensus forward P/E is the kind of number that makes you triple check because you don't think it can be right: 1,111x. Compare that 357x for CGC. It's a relative game with P/E ratios, so even though 357x may also sound extraordinarily rich, it goes to show that 1,111x is completely irrational.There is just so many ways for that multiple to get rerated downward, again and again. Final Note on Tilray StockThe first quarter earnings was a bit of a mixed bag. The market gave credit where it was due but no more than that, recognizing the weak points in the financials.Tilray has made progress on expansion via M&A, which may bolster future earnings, but only time will tell. There is a lot of success already built into the current valuation, meaning that TLRY can't miss a beat. As of this writing, Luce Emerson did not hold a position in any of the aforementioned securities. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 Stocks to Buy that Lost 10% Last Week * Top 7 Dow Jones Stocks of 2019 -- So Far * 5 Service Stocks That Can Win the Trade War -- According to Goldman Sachs Compare Brokers The post Don't Let the Great Q1 Numbers Fool You into Buying Tilray Stock appeared first on InvestorPlace.
Marijuana stocks like Cronos (NASDAQ:CRON) look a bit creaky at the moment, and CRON stock may be Exhibit A in the case that the group is stalling out. Cronos stock has dropped by over one-third just since early March, with the near-term question whether a recent bottom can hold.Source: Shutterstock I'm skeptical it will. Valuation is a bit more reasonable than it was earlier this year, when I thought Cronos Group stock was overvalued. But CRON is hardly cheap. Analysts have turned bearish. And that bearishness seems to coincide with the core problem here.Cronos simply hasn't driven the right kind of narrative for a marijuana stock at this valuation. Looking around the sector, there are concise, obvious bull cases for most of the well-covered stocks. Outside of the nearly $2 billion in cash coming in from Altria (NYSE:MO), Cronos lacks that case. And until that changes, Cronos is likely to struggle.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 6 Chinese Stocks That Could Pop On a Trade Deal The Need for a StoryInvesting in cannabis stocks at the moment isn't about the fundamentals. This is an industry at the very beginning of its growth. Price/earnings and even price/sales multiples are enormous and not necessarily comparable. The fundamental toolkit an investor might use to value a mature company simply doesn't apply in the sector at the moment.And so both the decision to invest in the sector at all, and which cannabis stock to choose, come down largely to long-term projections and even feel. Will the industry grow for years, as proponents argue? Is the oversupply already seen in legalized U.S. markets like Oregon a long-term risk? When does broader U.S. legalization arrive? Who of the myriad publicly traded cannabis plays wins and who loses?In that type of investing environment, a stock needs a succinct bull case, an elevator pitch so to speak. And most of the well-covered cannabis plays have that type of case. Canopy Growth (NYSE:CGC) is the early leader, and thanks to Constellation Brands (NYSE:STZ,NYSE:STZ.B) has the largest war chest. Aurora Cannabis (NYSE:ACB) is taking so many shots on goal that it's likely to score on at least one of them. Charlotte's Web (OTCMKTS:CWBHF) is the pure play on CBD (cannabidiol) oil. Even struggling Tilray (NASDAQ:TLRY) may have positioned itself to win if capacity gets overbuilt. And so on. What Is the Story Behind CRON Stock?What's the story behind CRON stock, however? The company has a ton of cash coming in, to be sure. But its production capabilities aren't particularly impressive: as The Motley Fool noted, Cronos isn't even in the top ten in terms of available capacity. Its Spinach retail brand doesn't appear as strong as those from Canopy or Hexo (NYSE:HEXO). Its positioning in the Canadian adult-use market seems behind that of many peers.Even analysts somewhat favorable to the stock aren't sure what to make of it, as James Brumley noted earlier this month. CIBC World Markets analyst John Zamparo wrote that the company hadn't given much colors on its plans for actually using that capital. Cannacord Genuity cited "a number of strategic initiatives that could eventually unlock longer-term value."Those aren't compelling points in favor of Cronos stock. Rather, they're something more akin to a "poke and hope" strategy. Cronos has a lot of cash, and the marijuana industry should grow, so the company will eventually figure something out. That kind of case might work in the middle of 2018, or the beginning of 2019, when marijuana stocks on the whole are soaring. As we've seen of late, however, it can't work forever. Cronos Group Stock Isn't CheapMeanwhile, Cronos remains priced in line with those peers who have better stories - and better growth. Cronos' Q1 report wasn't particularly impressive either fundamentally or in terms of management commentary. The company did turn a profit but only thanks to non-cash benefits, some of which related to the Altria deal. On an operating basis, Cronos continues to lose money.That's not a problem on its own: most stocks in the space are posting operating losses as they build out production, processing, and supply chain capabilities. But CRON, relative to revenue, continues to be valued roughly in line with the leaders of the space.That's not going to hold if Cronos can't prove that it will be a leader long-term. Right now, it's not making a good enough case - and until that changes, Cronos stock is going to underperform. And with marijuana stocks right now seeming to stall out, that in turn suggests that CRON is headed below $15.As of this writing, Vince Martin has no positions in any securities mentioned. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 Stocks to Buy that Lost 10% Last Week * Top 7 Dow Jones Stocks of 2019 -- So Far * 5 Service Stocks That Can Win the Trade War -- According to Goldman Sachs Compare Brokers The post Without a Better Story, Cronos Stock May Have Further to Fall appeared first on InvestorPlace.
This logic holds true in the cannabis space, where only some companies boast ample capital and are backed by a strong management team, CNBC's Jim Cramer said during his daily "Mad Money" show Thursday. Shares of Tilray Inc (NASDAQ: TLRY) briefly soared from $100 to $300 per share ahead of recreational legalization in Canada, Cramer said. When Tilray became a public company in the summer of 2018, CEO Brendan Kennedy was "very, very, very, very, very, very, very, very positive about the whole industry — but in retrospect, maybe too positive?" Cramer said.
Every so often, Wall Street experiences a craze that is fascinating like Bitcoin in 2017. But now it's the cannabis stocks and Tilray (NASDAQ:TLRY) has been a wild one to watch. It went public last year and within two months it had rallied 1,000%. 2019 has not been kind to TLRY stock as it's down 32% year-to-date, yet it is still up 110% since its inception. Compare that to the S&P 500, which is barely up 2% in a year.Source: Shutterstock Today's write up is to encourage those who like the stock to hold it and to also discourage those who want to short it. For full disclosure, I am not long Tilray nor am I an uber fan or a perma-bull of it.While the IPO was orderly, the period that followed was bonkers. In September it spiked to its $300 all-time high from $93 in three days. Clearly, it was a massive short squeeze where buying begot buying until the equilibrium was restored.InvestorPlace - Stock Market News, Stock Advice & Trading TipsUnfortunately for the Tilray stock bulls that was the high mark and it has traded horrendously since then. It is now below $50 and it can't sustain a rally. It's not so much that the fundamentals have deteriorated greatly. It is simply that the stock trade broke from the massive artificial rally. It takes time to restore the natural price action.TLRY still has not grabbed the attention of major corporations. Canopy Growth (NYSE:CGC) and Cronos (NASDAQ:CRON) got billions from Constellation Brands (NYSE:STZ) and Altria (NYSE:MO). Tilray is still going at it alone and it's struggling. It will need better alliances or it risks falling behind.Before you send me hate mail on this, I am not calling TLRY stock dead. Cannabis stocks are a special breed in this early stage. They are trying to establish the industry on Main Street and they may not be able to always impress Wall Street in the short term. There will be ups and downs but the bullish thesis is too diverse in scope to call it dead now. * 10 Baby Boomer Stocks to Buy So what's a fair value for TLRY stock? There is none because at this point they all carry massive market capitalization but with a tiny fraction of it in sales. TLRY's cap is $6 billion and it recently reported $23 million in sales.To that, management reported a big top line beat and 195% growth year over year. The stock spiked 6% on the headline and it is holding the zone decently given the overall stock market jitters. More importantly, its deliveries doubled year-over-year and that is the focus of many experts. They can't grow into their potential if they cannot deliver it as well as improve their margins along the way.The cannabis industry is still trying to adjust to its new legal status. This is a trend that is spotty for now but will grow its ubiquity with time. The U.S. market is an important one and many states will soon follow the ones that have already legalized it. But on the federal level, it may not be that easy. Luckily there are dozens of other countries for TLRY to potentially serve. Bottom Line on TLRY StockThe hoopla around cannabis stocks like Tilray is that they will disrupt so many huge markets that their upside potential should also be massive. The recreational use is what first comes to mind to most people but there are so many more like medicinal applications, potables and edibles. Maybe one day pot-based drinks will replace some of the soda, wine and beer consumption. * Top 7 Dow Jones Stocks of 2019 -- So Far Skeptics would call it a craze. Maybe, but unlike bitcoin where the concept escapes 99% of all people, everyone knows what cannabis is and is immediately interested in learning more about it. The allure of it is undeniable as I see evidence of the interest everywhere I go.So the bottom line is that although the experts can dismiss Tilray based on valuation and its distance from its all-time high, they would be making a mistake. Because as big as the potential of this multi-headed future area of business is, it will be impossible to quantify here let alone judge it right. Either avoid it altogether or plug your nose and buy the stock for the long term.We saw the skeptics lose fortunes trying to short Amazon (NASDAQ:NFLX) and Netflix (NASDAQ:NFLX). Netflix still gets a pass on profitability because of its global expansion potential as should most cannabis stocks … including TLRY stock.Nicolas Chahine is the managing director of SellSpreads.com. As of this writing, he did not hold a position in any of the aforementioned securities. You can follow him as @racernic on Twitter and Stocktwits. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 Stocks to Buy that Lost 10% Last Week * Top 7 Dow Jones Stocks of 2019 -- So Far * 5 Service Stocks That Can Win the Trade War -- According to Goldman Sachs Compare Brokers The post The Bullish Thesis for Tilray Stock Is Still Alive and Well appeared first on InvestorPlace.
Rosenblatt Securities analyst Hans Mosesmann maintained a Buy rating on Nividia and lowered the price target from $190 to $180. KeyBanc Capital Markets analyst Weston Twigg maintained a Sector Weight rating. Raymond James analyst Chris Caso reiterated an Outperform rating and $180 price target.
MercadoLibre (MELI) is seeing positive earnings estimate revisions suggesting that it could be a solid choice for investors.
Nvidia (NASDAQ:NVDA) reported earnings last night and investors loved them. NVDA stock spiked 7%… then faded back to red. This is more likely due to overall stock market malaise than Nvidia disappointment, however. We are still dealing with geopolitical headlines a major economic war between the U.S. and China.Source: via NvidiaAs of this writing, NVDA had turned green again, up about 1%.The NVDA options markets had priced in a +/- $12 move today and the after hour spike perfectly took the stock to the upper edge of that limit. The open interest in the options markets also suggested upside pressure with resistance this week at $173 and that was exactly where it faded. So the overnight action unfolded exactly as planned. Now the bulls need some follow through as the market shakes the overnight jitters off. And the geopolitical headlines need to cooperate.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 5 Service Stocks That Can Win the Trade War -- According to Goldman Sachs These last two days are quite the change from earlier this week when equities like NVDA were in free fall. Wall Street panicked from headlines that China retaliated against the new U.S. tariffs. Yet Thursday, NVDA stock closed slightly green ahead of the event.This small upside move was impressive since the Thursday open was scary for chip stocks. They all collapsed on headlines that the U.S. is acting against Huawei. So traders then extrapolated that all chip companies are vulnerable too. But this morning the sector is once again trying to find footing as Applied Materials (NASDAQ:AMAT) is helping with its positive reaction to their earnings.NVDA beat both earnings and sales. But more importantly, they raised guidance for the future. So they over-delivered and promised that they will do even better next time. This is reason to hold or start accumulating a position in Nvidia stock.NVIDIA used to be focused on graphics cards, but now they are set up to benefit from several of the hot topics for the next few decades. They have transformed into a dominant player in any tech that needs a brain. From computers on our desks or in our pockets, to ones that drive our cars.Last night's report shows that NVIDIA has returned to growth, and gaming and data centers are exciting areas of opportunities once more. Also Artificial Intelligence segments will accelerate as adoption of AI grows world wide. This is a budding trend that will dominate in the future. Every aspect of our technology will have AI built into it. Nvidia stock will surely benefit from this trend.Management also noted that the acquisition of Mellanox (NASDAQ:MLNX) will close by year end. So the noise from the assimilation will die down. They outbid Intel (NASDAQ:INTC) so they can create more runway in their own data center efforts. This will have incremental profits soon enough. The Bottom Line on Nvidia StockSo in summary, Nvidia stock is not a sell here. The management team has proven that they are still on top for their game. They are growing demand for gaming, cloud tech and AI. So they left nothing for the sellers to use as weapons.In addition, there is also the surprise revival of the Crypto-craze as Bitcoin rallied 100% in a month. In the past, NVDA and crypto moved in tandem, but Nvidia has outgrown this. Bitcoin is no longer part of the NVDA investment thesis so it's pure gravy. So it's not a threat to the rally since it's not a major peg that could break. * 6 Chinese Stocks That Could Pop On a Trade Deal The experts on Wall Street agree that Nvidia stock is a BUY. The average price target is close to $200 per share, which also shows that Wall Street believes that the upside opportunity outweighs the downside risks.Nicolas Chahine is the managing director of SellSpreads.com. As of this writing, he did not hold a position in any of the aforementioned securities. You can follow him as @racernic on Twitter and Stocktwits. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 Stocks to Buy that Lost 10% Last Week * Top 7 Dow Jones Stocks of 2019 -- So Far * 5 Service Stocks That Can Win the Trade War -- According to Goldman Sachs Compare Brokers The post After NVDA Stock Earnings, $200 Is Within Reach appeared first on InvestorPlace.